Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation (DAPA-AF)
Atrial Fibrillation
About this trial
This is an interventional treatment trial for Atrial Fibrillation focused on measuring Atrial Fibrillation
Eligibility Criteria
Inclusion Criteria
- Eligible for treatment with dapagliflozin per current FDA-approved indications, including: 1) heart failure (NYHA class II-IV) with reduced left ventricular ejection fraction (<50%), or 2) type 2 diabetes mellitus and established cardiovascular (CV) disease or multiple CV risk factors, or 3) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, 4) adults with chronic kidney disease at risk of progression as defined by the National Kidney Foundation as estimated GFR <60 ml/minute/1.73 m2.
- Scheduled to undergo ablation of symptomatic paroxysmal or persistent AF prior to date of randomization per current guideline indications.
- A glycated hemoglobin level < 10.5% during the past 6 calendar months prior to consent only in patients with type 2 diabetes mellitus
- Age > 18 years
- Existing functional CIED or planned to undergo CIED implant as SOC before or within 24 hours following the AF ablation procedure and prior to randomization date.
Exclusion Criteria
- Type 1 diabetes mellitus
- History of diabetic keto-acidosis
- Child Pugh Class C liver disease
- Last measured estimated GFR < 25 ml/minute/1.73 m2
- Pregnancy, plan to become pregnant <1 year after consent or breast feeding
- Current therapy with an SGLT2 inhibitor
- Hypersensitivity to dapagliflozin
- On heart transplant list or likely to undergo heart transplant
- Unwilling or unable to cooperate with the protocol
- Participation in other clinical trials (observational registries are allowed with approval).
- Unwilling to sign the consent for participation
- Life expectancy <1 year after consent date for any medical condition
Sites / Locations
- Maine Medical Center
- Henry Ford Hospital
- University of Rochester Medical Center
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Intervention Management Arm (Dapagliflozin)
Control Arm (Placebo)
A block randomization method will be use to randomize subjects to treatment with dapagliflozin 10 mg once daily. Subjects will take 1 blinded tablet of study drug (dapagliflozin) dosed once daily, per the randomization scheme, for 12 months. Each subject will be dispensed 35 blinded doses per month, during each month of participation in the trial. Quarterly pill counts will be performed to track compliance.
Subjects will take 1 blinded tablet of placebo drug dosed once daily, per the randomization scheme, for 12 months. Each subject will be dispensed 35 blinded doses per month, during each month of participation in the trial. Quarterly pill counts will be performed to track compliance.